

EDITORIAL

A Novel Therapeutic Approach to Breast Cancer using a Selective Cyclooxygenase 2 Inhibitor and Adenovirus-mediated Delivery of the Melanoma Differentiation-associated Gene-7 (Ad-mda7)

Young-Jin Suh, Kelly K. Hunt¹

Department of Surgery, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea; ¹Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

Recently, many preclinical and clinical researches have focused on the possible roles of new therapeutic modalities to enhance current treatment efficacy or to extend the current limitations against breast cancer treatment. The melanoma differentiation-associated gene-7 (*mda-7*), now classified as a member of the interleukin (IL)-10 gene family, has attracted attentions from several investigators for its unique ability to act against various cancers including breast cancer. In addition to *mda-7*, highly selective cyclooxygenase-2 (Cox-2) inhibitors, have continuously demonstrated possible anti-cancer effects against various cancers even though therapy

with many of the inhibitors has resulted in major set backs due to complications after long-term use. However, few have performed to demonstrate the synergistic effects of these two efficient treatment options or to demonstrate preventive measures to reduce the size of tumors. We summarize important results and our experience related to the use of a selective cyclooxygenase 2 inhibitor and adenovirus-mediated delivery of *mda-7*.

Key Words : *mda-7*, Celecoxib, Breast Cancer

INTRODUCTION

Breast cancer is the most prevalent cancer among women in Western countries. Although breast cancer is not the most prevalent cancer among women in developing countries like Korea, the number of newly diagnosed patients per year has been exponentially increasing.⁽¹⁾ Similar to other malignancies, breast cancer is a systemic disease characterized by local/regional and systemic dissemination after surgery with the intention to cure. The therapeutic modalities such as systemic chemotherapy, external irradiation and hormonal therapy are used in combination for the treatment of breast cancer. However, these aggressive treatments may cause moderate to severe adverse effects in patients while achieving the therapeutic goals. Therefore, many investigators are

studying methods to enhance the therapeutic efficacy of treatments while reducing the systemic burden of therapy. Among such methods, adenoviral delivery of certain proteins or genes and chemotherapeutic agents are being studied. The adenoviral delivery system is not a perfect vector for the delivery of genes and proteins, but the transfection efficiency of this vector is higher than any other vector, without compromising the host's immune defenses. The adenoviral delivery of the melanoma differentiation-associated gene 7 (Ad-mda7) was introduced to target malignant tumors, while sparing normal cells. Celecoxib, a highly selective cyclooxygenase 2 (COX-2) inhibitor, has proven to be effective for the treatment, and even for the prevention, of certain malignancies.

MELANOMA DIFFERENTIATION-ASSOCIATED GENE-7 (MDA-7)

Malignant tumors share many characteristics such as

Correspondence : Kelly K. Hunt

Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, TX, USA

Tel: 713-792-7216, Fax: 712-792-4689

E-mail : khunt@mdanderson.org

uncontrollable growth, repressed apoptosis and genetic abnormalities. Several steps are involved during the process of oncogenesis: some of them are beneficial to the host, but many of them are not. MDA-7 is a tumor suppressor that leads to apoptosis and cell death only for cancer cells;(2-13) its protein product has been identified and is referred to as IL-24.(14, 15) The complementary DNA (cDNA) of mda-7 was initially isolated by subtraction hybridization from a human melanoma cell line.(16, 17)

MDA-7 has been shown to have many anticancer properties such as cancer cell growth inhibition (18) and selective induction of apoptosis, only in cancer cells, *in vitro* and *in vivo*.(19) Expression of MDA-7 is regulated during human melanoma differentiation, during which AP-1 and C/EBP transcriptional factors are also present and play an important role.(20, 21) However, the expression of mda-7 has been shown to be suppressed or lost in human melanomas.(16, 22) The selective induction of apoptosis of mda-7 is mediated via the overexpression of the GADD family via p38 MAPK, beta-catenin, PI3K, BAX, JAK/STAT-independent pathway, JNK, and Fas.(10, 23-26) Furthermore, mda-7 has been shown to affect angiogenesis and vascular smooth muscle cells.(27-30)

CELECOXIB, A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR

Celecoxib, one of the highly selective COX-2 inhibitors, was initially introduced to treat arthritis.(31) Before the recent major setbacks, related to systemic complications after long-term use for arthritis, celecoxib and other analogues were prescribed to many patients with arthritis.(32) In addition, celecoxib and various derivatives have been shown to be therapeutic and possibly preventive against certain cancers including colon and breast cancer.(33-41) The evidence to date points to celecoxib inducing apoptosis and cell cycle arrest in cancers.(42-44) Different from the original indications for celecoxib, its use for cancer can be temporary, which would prevent some of the long-term side effects associated with cere-

brovascular function.(45)

Breast cancer is a malignant tumor shown to over-express COX-2.(46, 47) HER-2/*neu*-positive breast cancer is associated with a poor prognosis; activator protein-1 (AP-1) along with PEA-3 is involved in the COX-2 over-expression in HER-2/*neu*-positive breast cancer.(48) In addition, AP-1 may play a role in reducing COX-2 transcriptional activity in HER-2/*neu*-negative MCF-7 breast cancer cells with conjugated linoleic acid.(49) AP-1 has been shown to be related to mda-7 gene promoter activity.(21) In addition, GADD153 was recently shown to mediate celecoxib-induced programmed cell death in cervical cancer, *in vitro*.(50) In breast cancer cells, COX-2 is known to induce IL-11 synthesis.(51) These findings suggest a possible synergism between COX-2 inhibition and mda-7. Celecoxib appears to be involved in the modulation of signaling pathways, such as PI3K, Akt, beta-catenin, uPA, death receptor, caspase, NFκB, p21, and p27.(40, 41, 44, 52-59)

ADENOVIRAL GENE DELIVERY

Many vectors have been introduced to deliver genes, proteins and other molecules into target cells or organs. Adenovirus is a vector used frequently due to its safety and reliable handling. It has been considered for possible use in humans without major systemic problems. The transfection efficiency of the adenovirus, devoid of self replication, is superior to other physiological and mechanical methods. Though some possible generalized adverse reactions, after repetitive transfection with the adenovirus are a concern, it still is a promising vehicle for transfer. Additional research is needed to enhance the expression of target molecules or genes, while decreasing possible problems without compromising its therapeutic results. The expression of mda7 can be enhanced by the adenoviral-mediated delivery of celecoxib into breast cancer cells.

COMBINATION OF AD-MDA7 AND CELECOXIB

We previously reported the combined treatment of Ad-

mda7 and trastuzumab for HER-2/*neu*-overexpressing human breast cancer cells to enhance cell death.(60) Other studies have also reported on the effects of the combined use of celecoxib and chemotherapeutic or hormonal agents on cancer cells.(61-67) However, there are no reports on the combination of a selective COX-2 inhibitor, such as celecoxib and Ad-mda7, on any type of cancer cells, except for our report on their effect on breast cancer cells.(68, 69) Accidentally, we observed a synergistic enhancement of mda7 expression after the transfection of Ad-mda7 combined with celecoxib (unpublished data). We noted increased tumoricidal effects, apoptosis and decreased cancer cell growth after combination treatment compared to the effects of either alone. In addition, we observed decreased prostaglandin E₂ synthesis, expression of COX-2 and Akt phosphorylation. Since Akt, a key regulator of the estrogen receptor alpha, was decreased after combined treatment, this suggested promising use of such a combination for the treatment of cancer cells.(70) According to our experiences, the synergistic effects were not dependent on the expression of HER-2/*neu*. This implies that the combination treatment can be used for breast cancer without being affected by HER-2/*neu* expression. The combination showed somewhat different patterns of enhanced apoptosis for HER-2/*neu*-positive and -negative breast cancer cells. HER-2/*neu*-positive breast cancer cells were affected more during the early phase of apoptosis, while the opposite findings were observed in the HER-2/*neu*-negative breast cancer cells. The effects of the combined treatment on the cell cycle differed depending on the cell type according to the expression of HER-2/*neu*. In the HER-2/*neu*-positive cells, the G₁ phase was pronounced and the S phase fraction was significantly increased after combined treatment.

RADIOSENSITIZATION

Many breast cancer patients are candidates for breast-conserving surgery rather than mastectomies.(71, 72) In such cases, external radiation treatment after curative surgery is frequently used to target metastatic foci with

or without other treatments such as chemotherapeutic agents and hormonal agents. Many investigators have studied how to enhance the radiosensitivity of cancer cells including breast cancers. Ad-mda7 has shown radiosensitizing effects in a variety of cancer cells.(7, 73, 74) Aside from the known chemosensitization effects,(75, 76) selective COX-2 inhibitors, such as celecoxib, have also been shown to make cancer cells more susceptible to external irradiation.(77-79) However, a synergistic radiosensitization with Ad-mda7 and celecoxib, for breast cancer cells, has not been previously evaluated. We observed an enhanced radiosensitization with combined Ad-mda7 and celecoxib delivered prior to radiotherapy in breast cancer cells, *in vitro*. Although additional research is needed for confirmation of these findings this may provide a promising approach for enhancing radiation treatment.(80)

CONCLUSION

Ad-mda7 has unique characteristics including induction of apoptosis that targets only cancer cells. Celecoxib has shown therapeutic and preventive effects against various cancers. Our work on the combination of Ad-mda7 and celecoxib to increase the tumoricidal effects compared to the use of either alone, in breast cancer cells, requires additional study to elucidate the probable mechanisms or networks involved and to identify important signal molecules. After the accumulation of additional scientific evidence and associated data, a less toxic but more effective treatment approach with the combination of Ad-mda7 and celecoxib might be applicable to human therapy.

REFERENCES

1. The Korea Breast Cancer Society. Clinical characteristics of Korean breast cancer patients in 1998. The Korean Breast Cancer Society. J Korean Med Sci 2000;15:569-79.
2. Mahasreshti PJ, Kataram M, Wu H, Yalavarthy LP, Carey D, Fisher PB, et al. Ovarian cancer targeted adenoviral-mediated mda-7/IL-24 gene therapy. Gynecol Oncol 2006;100:521-32.

3. Zhao L, Gu J, Dong A, Zhang Y, Zhong L, He L, et al. Potent anti-tumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. *Hum Gene Ther* 2005;16:845-58.
4. Chen WY, Cheng YT, Lei HY, Chang CP, Wang CW, Chang MS. IL-24 inhibits the growth of hepatoma cells in vivo. *Genes Immunol* 2005;6:493-9.
5. Ramesh R, Ito I, Gopalan B, Saito Y, Mhashilkar AM, Chada S. Ectopic production of MDA-7/IL-24 inhibits invasion and migration of human lung cancer cells. *Mol Ther* 2004;9:510-8.
6. Lebedeva IV, Su ZZ, Sarkar D, Kitada S, Dent P, Waxman S, et al. Melanoma differentiation associated gene-7, mda-7/interleukin-24, induces apoptosis in prostate cancer cells by promoting mitochondrial dysfunction and inducing reactive oxygen species. *Cancer Res* 2003;63:8138-44.
7. Su ZZ, Lebedeva V, Sarkar D, Gopalkrishnan RV, Sauane M, Sigmon C, et al. Melanoma differentiation associated gene-7, mda-7/IL-24, selectively induces growth suppression, apoptosis and radiosensitization in malignant gliomas in a p53-independent manner. *Oncogene* 2003;22:1164-80.
8. Yacoub A, Mitchell C, Brannon J, Rosenberg E, Quao L, McKinstry R, et al. MDA-7 (interleukin-24) inhibits the proliferation of renal carcinoma cells and interacts with free radicals to promote cell death and loss of reproductive capacity. *Mol Cancer Ther* 2003;2:623-32.
9. Saeki T, Mhashilkar A, Swanson X, Zou-Yang XH, Sieger K, Kawabe S, et al. Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo. *Oncogene* 2002;21:4558-66.
10. Mhashilkar AM, Stewart AL, Sieger K, Yang HY, Khimani AH, Ito I, et al. MDA-7 negatively regulates the beta-catenin and PI3K signaling pathways in breast and lung tumor cells. *Mol Ther* 2003;8:207-19.
11. Lebedeva IV, Su ZZ, Chang Y, Kitada S, Reed JC, Fisher PB. The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells. *Oncogene* 2002;21:708-18.
12. Huang EY, Madireddi MT, Gopalkrishnan RV, Leszczyniecka M, Su Z, Lebedeva IV, et al. Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. *Oncogene* 2001;20:7051-63.
13. Saeki T, Mhashilkar A, Chada S, Branch C, Roth JA, Ramesh R. Tumor-suppressive effects by adenovirus-mediated mda-7 gene transfer in non-small cell lung cancer cell in vitro. *Gene Ther* 2000;7:2051-7.
14. Sauane M, Gopalkrishnan RV, Sarkar D, Su ZZ, Lebedeva IV, Dent P, et al. MDA-7/IL-24: novel cancer growth suppressing and apoptosis inducing cytokine. *Cytokine Growth Factor Rev* 2003;14:35-51.
15. Caudell EG, Mumm JB, Poindexter N, Ekmekcioglu S, Mhashilkar AM, Yang XH, et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. *J Immunol* 2002;168:6041-6.
16. Ellerhorst JA, Prieto VG, Ekmekcioglu S, Broemeling L, Yekell S, Chada S, et al. Loss of MDA-7 expression with progression of melanoma. *J Clin Oncol* 2002;20:1069-74.
17. Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. *Oncogene* 1995;11:2477-86.
18. Jiang H, Su ZZ, Lin JJ, Goldstein NI, Young CS, Fisher PB. The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. *Proc Natl Acad Sci USA* 1996;93:9160-5.
19. Su ZZ, Madireddi MT, Lin JJ, Young CS, Kitada S, Reed JC, et al. The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. *Proc Natl Acad Sci USA* 1998;95:14400-5.
20. Madireddi MT, Dent P, Fisher PB. Regulation of mda-7 gene expression during human melanoma differentiation. *Oncogene* 2000;19:362-8.
21. Madireddi MT, Dent P, Fisher PB. AP-1 and C/EBP transcription factors contribute to mda-7 gene promoter activity during human melanoma differentiation. *J Cell Physiol* 2000;185:36-46.
22. Ekmekcioglu S, Ellerhorst J, Mhashilkar AM, Sahin AA, Read CM, Prieto VG, et al. Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas. *Int J Cancer* 2001;94:54-9.
23. Sarkar D, Su ZZ, Lebedeva IV, Sauane M, Gopalkrishnan RV, Valerie K, et al. mda-7 (IL-24) Mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK. *Proc Natl Acad Sci USA* 2002;99:10054-9.
24. Chada S, Bocangel D, Ramesh R, Grimm EA, Mumm JB, Mhashilkar AM, et al. mda-7/IL2 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer. *Mol Ther* 2005;11:724-33.

25. Cao XX, Mohuiddin I, Chada S, Mhashilkar AM, Ozvaran MK, McConkey DJ, et al. Adenoviral transfer of mda-7 leads to BAX up-regulation and apoptosis in mesothelioma cells, and is abrogated by overexpression of BCL-XL. *Mol Med* 2002;8:869-76.
26. Sauane M, Gopalkrishnan RV, Lebedeva I, Mei MX, Sarkar D, Su ZZ, et al. Mda-7/IL-24 induces apoptosis of diverse cancer cell lines through JAK/STAT-independent pathways. *J Cell Physiol* 2003;196:34-45.
27. Ramesh R, Mhashilkar AM, Tanaka F, Saito Y, Branch CD, Sieger K, et al. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. *Cancer Res* 2003;63:5105-13.
28. Chen J, Chada S, Mhashilkar A, Miano JM. Tumor suppressor MDA-7/IL-24 selectively inhibits vascular smooth muscle cell growth and migration. *Mol Ther* 2003;8:220-9.
29. Yacoub A, Mitchell C, Lebedeva IV, Sarkar D, Su ZZ, McKinstry R, et al. mda-7 (IL-24) inhibits growth and enhances radiosensitivity of glioma cells in vitro via JNK signaling. *Cancer Biol Ther* 2003;2:347-53.
30. Gopalan B, Litvak A, Sharman S, Mhashilkar AM, Chada S, Ramesh R. Activation of the Fas-FasL signaling pathway by MDA-7/IL-24 kills human ovarian cancer cells. *Cancer Res* 2005;65:3017-24.
31. van Ryn J, Pairet M. Selective cyclooxygenase-2 inhibitors: pharmacology, clinical effects and therapeutic potential. *Expert Opin Investig Drugs* 1997;6:609-14.
32. Dogne JM, Hansen J, Supuran C, Pratico D. Coxibs and cardiovascular side-effects: from light to shadow. *Curr Pharm Des* 2006;12:971-5.
33. Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. *BMC Cancer* 2006;6:27.
34. Kundu N, Walser TC, Ma X, Fulton AM. Cyclooxygenase inhibitors modulate NK activities that control metastatic disease. *Cancer Immunol Immunother* 2005;54:981-7.
35. Basu GD, Pathangey LB, Tinder TL, Lagiola M, Gendler SJ, Mukherjee P. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in a in vivo model of spontaneous metastatic breast cancer. *Mol Cancer Res* 2004;2:632-42.
36. Guastalla JP, Bachelot T, Ray-Coquard I. Cyclooxygenase 2 and breast cancer. From biological concept to clinical trials. *Bull Cancer* 2004;91(S2):S99-108.
37. Howe LR, Subbaramaiah K, Brown AM, Dannenberg AJ. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. *Endocr Relat Cancer* 2001;8:97-114.
38. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. *J Biol Chem* 2000;275:11397-403.
39. Yamada Y, Yoshimi N, Hirose Y, Hara A, Shimizu M, Kuno T, et al. Suppression of occurrence and advancement of beta-catenin-accumulated crypts, possible premalignant lesions of colon cancer, by selective cyclooxygenase-2 inhibitor, celecoxib. *Jpn J Cancer Res* 2001;92:617-23.
40. Alshafie GA, Abou-Issa HM, Seibert K, Harris RE. Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. *Oncol Rep* 2000;7:1377-81.
41. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. *Cancer Res* 1998;58:409-12.
42. Han C, Leng J, Demetris AJ, Wu T. Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. *Cancer Res* 2004;64:1369-76.
43. Johnson AJ, Song X, Hsu A, Chen C. Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells. *Adv Enzyme Regul* 2001;41:221-35.
44. Dvory-Sobol H, Cohen-Noyman E, Kazanov D, Figer A, Birkenfeld S, Madar-Shapiro L, et al. Celecoxib leads to G2/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner. *Eur J Cancer* 2006;42:422-6.
45. Vanchieri C. Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention. *J Natl Cancer Inst* 2005;97:552-3.
46. Arun B, Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. *Semin Oncol* 2004;31(2 Suppl 7):22-9.
47. Lanza-Jacoby S, Miller S, Flynn J, Gallatig K, Daskalakis C, Masferrer JL, et al. The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. *Cancer Epidemiol Biomarkers Prev* 2003;12:1486-91.
48. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. *J Biol Chem* 2002;277:18649-57.
49. Degner SC, Kemp MQ, Bowden GT, Romagnolo DF. Conjugated linoleic acid attenuates cyclooxygenase-2 transcriptional activity via

- an anti-AP-1 mechanism in MCF-7 breast cancer cells. *J Nutr* 2006; 136:421-7.
50. Kim SH, Hwang CI, Park WY, Lee JH, Song YS. GADD153 mediates celecoxib-induced apoptosis in cervical cancer cells. *Carcinogenesis* 2007;28:223-31.
 51. Singh B, Berry JA, Shorer A, Lucci A. COX-2 induce IL-11 production in human breast cancer cells. *J Surg Res* 2006;131:267-75.
 52. Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau YJ, et al. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. *Cancer Res* 2004;64:4309-18.
 53. Kucab JE, Lee C, Chen CS, Zhu J, Gilks CB, Cheang M, et al. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. *Breast Cancer Res* 2005;7:796-807.
 54. Maier TJ, Janssen A, Schmidt R, Geisslinger G, Grosch S. Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. *FASEB J* 2005;19:1353-5.
 55. Andrews HN, Habibi G, Kucab JE, Dunn SE. Celecoxib inhibits urokinase-type plasminogen activator (uPA) production in MDA-MB-231 breast cancer cells. *Breast Cancer Res Treat* 2005;94:47-52.
 56. Liu X, Yue P, Zhou Z, Khuri FR, Sun SY. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. *J Natl Cancer Inst* 2004;96:1769-80.
 57. Ding H, Han C, Zhu J, Chen CS, D'Ambrosio SM. Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. *Int J Cancer* 2005; 113:803-10.
 58. Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P. Mechanisms underlying the growth inhibitory effects of the cyclooxygenase-2 inhibitor celecoxib in human breast cancer cells. *Breast Cancer Res* 2005;7:R422-35.
 59. Shishodia S, Koul D, Aggarwal BB. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human on-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. *J Immunol* 2004;173:2011-22.
 60. McKenzie T, Liu Y, Fanale M, Swisher SG, Chada S, Hunt KK. Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells. *Surgery* 2004; 136:437-42.
 61. Fulzele SV, Shaik MS, Chatterjee A, Singh M. Anti-cancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549. *J Pharm Pharmacol* 2006;58:327-36.
 62. Ferrari V, Valcamonica F, Amoroso V, Simoncini E, Vassalli L, Marpicati P, et al. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial. *Cancer Chemother Pharmacol* 2006;57:185-90.
 63. Csiki I, Morrow JD, Sandler A, Shyr Y, Oates J, Williams MK, et al. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel. *Clin Cancer Res* 2005;11: 6634-40.
 64. Dandekar DS, Lopez M, Carey RI, Lokeshwar BL. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-2 and -9 in prostate cancer cells. *Int J Cancer* 2005;115:484-92.
 65. Chow LW, Cheng CW, Wong JL, Toi M. Serum lipid profiles in patients receiving endocrine treatment for breast cancer the results from the Celecoxib Anti-Aromatase Neoadjuvant (CAAN) Trial. *Biomed Pharmacother* 2005;59(S2):S302-5.
 66. Chow LW, Loo WT, Wai CC, Lui EL, Zhu L, Toi M. Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-fluorouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients. *Biomed Pharmacother* 2005;59(S2):S298-301.
 67. Bundred NJ, Bames NL. Potential use of COX-2-aromatase inhibitor combinations in breast cancer. *Br J Cancer* 2005;93(S1):S10-5.
 68. Suh YJ, Chada S, McKenzie T, Liu Y, Swisher SG, Lucci A, et al. Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells. *Surgery* 2005;138:422-30.
 69. Oida Y, Gopalan B, Miyahara R, Inoue S, Branch CD, Mhashilkar AM, et al. Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. *Mol Cancer Ther* 2005; 4:291-304.
 70. Guo S, Sonenshein GE. Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is replaced by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway. *Mol Cell Biol* 2004;24:8681-90.
 71. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. *N Engl J Med* 2002;347:1227-32.
 72. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing

- total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. *N Engl J Med* 2002;347:1233-41.
73. Chada S, Mhashilkar AM, Liu Y, Nishikawa T, Bocangel D, Zheng M, et al. mda-7 gene transfer sensitizes breast carcinoma cells to chemotherapy, biologic therapies and radiotherapy: correlation with expression of bcl-2 family members. *Cancer Gene Ther* 2006;13:490-502.
74. Kawabe S, Nishikawa T, Munshi A, Roth JA, Chada S, Meyn RE. Adenovirus-mediated mda-7 gene expression radiosensitizes non-small cell lung cancer cells via TP53-independent mechanisms. *Mol Ther* 2002;6:637-44.
75. Awara WM, El-Sisi AE, El-Sayad ME, Goda AE. The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin? *Pharmacol Res* 2004;50:487-98.
76. Merchan JR, Jayaram DR, Supko JG, He X, Bublely GJ, Sukhatme VP. Increased endothelial uptake of paclitaxel as a potential mechanism for its Antiangiogenic effects: potentiation by Cox-2 inhibition. *Int J Cancer* 2005;113:490-8.
77. Shin YK, Park JS, Kim HS, Jun HJ, Kim GE, Suh CO, et al. Radio-sensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. *Cancer Res* 2005;65:9501-9.
78. Raju U, Ariga H, Dittmann K, Nakata E, Ang KK, Milas L. Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib. *Int J Radiat Biol Phys* 2005;63:520-8.
79. Cerchietti LC, Bonomi MR, Navigante AH, Castro MA, Cabalar ME, Roth BM. Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases. *J Neurooncol* 2005;71:73-81.
80. Su ZZ, Lebedeva IV, Sarkar D, Emdad L, Gupta P, Kitada S, et al. Ionizing radiation enhances therapeutic activity of mda-7/IL-24: overcoming radiation- and mda-7/IL-24-resistance in prostate cancer cells overexpressing the antiapoptotic proteins bcl-x(L) or bcl-2. *Oncogene* 2006;25:2339-48.